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Antimicrobial resistance is a global public health challenge and the development of new antibiotics is 
scarce. The inherent property of conventional antibiotics to impose selective pressure on bacteria, 
together with their misuse and overuse, contributed to the development of multi-resistant 
pathogens. Methicillin-resistant Staphylococcus aureus (MRSA) is one of these ‘superbugs’. In both 
healthcare and community settings, MRSA is a major cause of infections worldwide.1 In addition to 
this, staphylococcal pathogens are a frequent cause of biofilm-associated infections.2 Bacterial cells 
within a biofilm are protected from attack by the immune system and antibiotics often fail to pierce 
the biofilm matrix.  
Hamamelitannin (HAM), a natural product isolated from the witch hazel (Hamamelis virginiana) has 
recently been identified as an antimicrobial potentiator and may be used in the fight against biofilm-
related staphylococcal infections.3 HAM increases the susceptibility of S. aureus biofilms towards 
vancomycin (VAN) in vitro as well as in vivo.3,4 
A first round of hit to lead optimization of HAM led to bisbenzamide 1, with enhanced druglikeness. 
Starting from this HAM-derived pharmacophore, we focused on optimizing potency further. Our 
work resulted in the identification of compound 2 with potent in vitro activity and exceptional 
antibiofilm activity in a Caenorhabditis elegans infection model and a murine mastitis model, while 
lacking cytotoxicity against MRC-5 lung fibroblast cells. 
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